key: cord-0937176-93y40vnp
authors: Shook, Lydia L.; Sullivan, Elinor L.; Lo, Jamie O.; Perlis, Roy H.; Edlow, Andrea G.
title: COVID-19 in pregnancy: implications for fetal brain development
date: 2022-02-14
journal: Trends Mol Med
DOI: 10.1016/j.molmed.2022.02.004
sha: c81746c1c0719703e633368168f2b96fa42c7b52
doc_id: 937176
cord_uid: 93y40vnp

The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy on the developing fetal brain is poorly understood. Other antenatal infections such as influenza have been associated with adverse neurodevelopmental outcomes in offspring. Although vertical transmission has been rarely observed in SARS-CoV-2 to date, given the potential for profound maternal immune activation, impact on the developing fetal brain is likely. Here we review evidence that SARS-CoV-2 and other viral infections during pregnancy can result in maternal, placental and fetal immune activation, and ultimately in offspring neurodevelopmental morbidity. Finally, we highlight the need for cellular models of fetal brain development to better understand potential short- and long-term impacts of maternal SARS-CoV-2 infection on the next generation.

Some viral infections acquired antenatally can have lasting, potentially devastating, impacts on the developing fetal brain. Those viruses that demonstrate neuroinvasion and neurotropismthat is, the ability to invade the blood-brain-barrier and infect neurologic tissue, such as Zika virus or cytomegalovirus (CMV)can directly damage the developing fetal brain if transplacental transmission occurs. [1, 2] Other infections that do not cross the placental barrier, including viral infections such as influenza, have also been consistently associated with adverse neurodevelopmental outcomes in offspring, primarily via mechanisms related to maternal, placental, and subsequent fetal brain immune activation. [3] [4] [5] [6] [7] [8] Adverse neurodevelopmental outcomes observed following prenatal infection range from autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) and cognitive dysfunction, to anxiety, depression, and schizophrenia. [3, 4, [7] [8] [9] [10] [11] [12] [13] Past pandemics have provided a window into potential neurodevelopmental consequences in subsequent generations. For example, individuals who were fetuses during the 1957 influenza pandemic had an increased risk for being hospitalized for schizophrenia as adults. [12] The rubella pandemic of 1964 was associated with a 10-15-fold increase in ASD and schizophrenia in offspring. [14] In a cohort of more than 115,000 pregnancies, fevers in pregnancy were associated with an increased odds ratio (OR) of up to 3.1 for ASD. [11] The potential for neurodevelopmental morbidity in offspring exposed prenatally to SARS-CoV-2 is therefore of great concern. Given the large number of exposed individuals, even a modest increase in risk for adverse offspring neurodevelopment would still have a massive public health impact. [15] [16] [17] [18] [19] [20] More than 59 million people in the United States and 300 million worldwide have been diagnosed with COVID-19, [21] including over 155,500 pregnant women in the United States. [22] With approximately 140 million live births occurring annually worldwide, [23] and the prevalence of SARS-CoV-2 positivity in pregnant women as high as 15% in urban centers, [24] the numbers of children exposed to maternal COVID-19 infection in utero worldwide could reach up to 20 million per year, particularly in the setting of low COVID-There are multiple potential pathways by which a maternal infection with SARS-CoV-2 could impact the developing fetal brain: [13, [28] [29] [30] [31] 1) via maternal immune activation during key neurodevelopmental windows in pregnancy; 2) via direct fetal infection of neurologic tissues via transplacental transmission of virus; or 3) via compromised placental function resulting in adverse pregnancy outcomes associated with an increased risk of neurologic injury (e.g. fetal growth restriction, preterm birth, abruption). In this review, we present emerging evidence regarding the impact of SARS-CoV-2 infection during pregnancy on offspring neurodevelopmental outcomes, explore potential mechanisms by which prenatal SARS-CoV-2 exposure might impact the developing fetal brain, and discuss virus and host factors which might influence risk. Lastly, we discuss the need for cellular models to best study the impact of SARS-CoV-2 on the developing brain, and to identify individuals most at risk for adverse outcomes who may benefit from early intervention or therapeutics.

Mounting evidence suggests that SARS-CoV-2 infection can cause both acute and chronic neurologic and psychiatric sequelae in adult and pediatric populations. [32] [33] [34] [35] [36] [37] A recent study from the UK suggests that 3.8% of children hospitalized with COVID-19 experience a neurologic complication that also have long-term consequences, ranging from behavioral change, hallucinations and encephalopathy, to status epilepticus, encephalitis, Guillain-Barre/acute demyelinating syndromes, chorea and psychosis. [38] A persistent problem in interpreting these data is the paucity of studies with well-matched controlsfor example, to understand whether these sequelae reflect direct effects of SARS-CoV-2, or simply the consequences of any severe illness requiring hospitalization. One early report using neurocognitive assessments suggested that the pattern of deficits in adults was nonspecific, consistent with other complicated hospitalizations. [39] Still, in aggregate these results suggest at least the possibility that SARS-CoV-2whether via inflammation or immune-mediated mechanisms or via direct infection of the central nervous system-can have lasting impact on the developed (and therefore likely also on the developing) brain.

Early signals of adverse neurodevelopmental outcomes at 3-6 months, one year, and 1.5 years in infants and children exposed to SARS-CoV-2 in utero, and/or born during the COVID-J o u r n a l P r e -p r o o f exposure to SARS-CoV-2 in China identified deficits in social-emotional domain of neurodevelopmental testing at 3 months of age.

[43] A preliminary report of 298 infants born to women with SARS-CoV-2 infection during pregnancy found evidence of developmental delay in 10% of infants at 12 months of age, although neither study included a non-infected comparator group. [44] Another preliminary report of over 7,000 infants born during the COVID-19 pandemic to both SARS-CoV-2 infected and non-infected mothers identified an association between maternal SARS-CoV-2 exposure and a neurodevelopmental diagnosis at 12 months. [27] Importantly, that study found that while the association between maternal SARS-CoV-2 exposure and offspring neurodevelopmental morbidity was enhanced by preterm delivery, the presence of a neurodevelopmental diagnosis was not entirely explained by prematurity, suggesting a more specific mechanism of effect than simply SARS-CoV-2 contributing to pregnancy complications. Whether a definitive connection exists between prenatal SARS-CoV-2 exposure and neurodevelopmental disorders in offspring is not yet known, in part because most children born to women infected in the first wave of the pandemic are still too young for reliable diagnosis of many neurodevelopmental conditions. Despite the significant limitations of epidemiologic and clinical data sets in defining causality or mechanism, these preliminary data demonstrate the potential for prenatal SARS-CoV-2 exposure to impact early neurodevelopmental outcomes.

Convergent data from animal models have demonstrated that maternal immune activation (see Glossary), rather than a specific virus or bacterial infection, is likely the final common pathway by which most maternal infections confer offspring neurodevelopmental morbidity. [45, 46] Rodent and non-human primate models have utilized multiple techniques to activate the maternal immune system, including the viral mimic polyinosinic-polycytidylic (poly[I:C]), a synthetic double-stranded RNA, demonstrating alterations in offspring brain immune function, and behavioral and neuroimaging correlates of ASD and schizophrenia [47- J o u r n a l P r e -p r o o f 57]. Rodent models of maternal influenza infection resulted in offspring behavioral phenotypes consistent with ASD and psychosis, [58] but many of the same behavioral abnormalities were present when uninfected rodent mothers were injected with poly[I:C], [58] suggesting that MIA rather than any specific pathogen mediates the neurodevelopmental morbidity in offspring. [57, 59] Immune cell populations, effector cytokines and inflammatory markers critical in mediating abnormal offspring behavioral phenotypes in models of maternal immune activation include T helper 17 (TH17) cells/IL-17, IL-6, IL-1R, TNF-, IL-10, CRP, and the complement system, among others. [10, [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] Many of these same cytokines and inflammatory markers are also dysregulated in COVID-19 infection in the non-pregnant population. [73] [74] [75] [76] [77] [78] [79] [80] 

Although the immune and inflammatory response to SARS-CoV-2 in pregnancy is only beginning to be characterized, early data show a pro-inflammatory cytokine phenotype in pregnant women with active SARS-CoV-2, with IFN-, IL1-, and IL-6 most implicated, particularly in cases of severe COVID-19 disease. [81, 82] Several studies have demonstrated the potential for maternal SARS-CoV-2 infection to stimulate an intense placental immune and inflammatory response, [83] [84] [85] both in the presence (rare) [85] and absence (more common) [84, 86, 87] of direct SARS-CoV-2 infection of the placenta. Substantial infiltration of maternal immune cells into the placenta has been observed in cases of severe maternal COVID-19 disease, adverse neonatal outcomes, and heavy placental SARS-CoV-2 viral burden. [85] In addition, maternal SARS-CoV-2 infection is associated with hyperplasia and/or increased density of fetal placental macrophages or Hofbauer cells, typically in the absence of Hofbauer cell infection. [84, 88] In placental samples without evidence of direct SARS-CoV-2 infection, transcriptomic analysis has demonstrated upregulation of inflammatory pathways of maternal decidual natural killer (NK) and T cells and upregulation of interferon (IFN)-stimulated genes (ISGs) in placental villous tissue. [83, 84] Notable sex differences have been observed in the placental immune response to maternal SARS-CoV-2, [84] which suggests that sex plays an important role in fetal and offspring vulnerability to maternal SARS-CoV-2 infection.

Increased cord blood cytokine levels and altered cord blood immune cell profiles including increased proportion of NK cells, Vδ2+ γδ T cells, and regulatory T cells have been J o u r n a l P r e -p r o o f observed in maternal SARS-CoV-2 infection in the absence of fetal infection, [89, 90] pointing to the potential for MIA itself to generate a pro-inflammatory fetal response. Single-cell RNA sequencing (scRNA-seq) of cord blood mononuclear cells demonstrates a significant impact of maternal SARS-CoV-2 on cord blood monocyte programs, with ISGs upregulated in CD14+ and CD16+ monocytes. [91] Importantly, observed fetal immune imprinting to date has been nonspecific to SARS-CoV-2, occurring in the absence of vertical transmission. [90, 92] How can maternal and placental immune activation and inflammation impact the developing fetal brain?

Several candidate mechanisms have been proposed in models of MIA which may apply to maternal SARS-CoV-2 infection as well ( Figure 1 ). 1) Maternal immune activation is associated with rapid induction of immune (e.g. Type I-III IFN pathways) and pro-inflammatory responses (e.g. TNF-, IL-6, IL-1) in the placenta and the developing fetal brain, particularly in the setting of activation via TLR7/8 signaling pathways, and to a lesser extent for immune activation via TLR3/TLR4 signaling pathways; [45, [93] [94] [95] [96] 2) Dysregulated placental serotonin signaling, as the placenta is the primary source of serotonin for the developing fetal brain. [97, 98] Both maternal and placental immune activation and inflammation alter placental serotonin signaling, which in turn influences fetal brain development via impaired synaptogenesis, neuronal migration, and axonal targeting; [98] [99] [100] [101] [102] 3) Maternal and placental immune activation are also associated with other alterations in fetal brain neurotransmitter signaling, including the dopaminergic, cholinergic, GABAergic, glutamatergic, and melanocortinergic systems (the latter mediated primarily by dysregulated leptin signaling), that influence fetal brain development and future risk for conditions such as schizophrenia, addiction, and disordered eating; [103] [104] [105] [106] [107] [108] [109] 4) Maternal and placental immune activation are associated with placental and fetal brain mitochondrial dysfunction, oxidative stress, and disrupted protein homeostasis. [93, 96, 110, 111] .

The maternal and offspring gut microbiome may also be important modifiers of the impact of maternal immune activation on the developing brain and offspring outcomes. [60, 111, 112] Maternal immune activation models have pointed to aberrant programming of fetal microglia and dysregulation of cytokine networks as key mechanisms underlying abnormal fetal brain development, with microglia primed toward a pro-inflammatory phenotype and altered J o u r n a l P r e -p r o o f synaptic pruning implicated in offspring morbidity. [63, [113] [114] [115] [116] Given the extent of synapse formation and pruning that occurs in fetal and neonatal life [117] [118] [119] [120] , developmental microglial function represents a critical target for investigation to better understand the impact of SARS-CoV-2-driven immune activation on the developing fetal brain. Maternal immune activation has also been associated with abnormalities of offspring neural progenitor cell proliferation; impaired neuronal migration; alterations in neuronal density and perineuronal nets; altered dendrite structure, synaptogenesis, and synaptic function and plasticity; and changes in interhemispheric and corticolimbic connectivity. [109, 111, 121, 122] . Thus, in utero exposure to SARS-CoV-2-related maternal immune activation may be associated with altered development of multiple brain cell types and functions, with the timing of the insult, presence or absence of other exposures, and intrinsic fetal characteristics such as fetal sex or genetic susceptibility dictating fetal resilience or vulnerability.

Transplacental transmission of virus capable of infecting neural tissue can have lasting and devastating consequences on the developing fetal brain. A key factor in understanding potential fetal infection risk is whether maternally-acquired SARS-CoV-2 can transmit across the placenta, the primary physiological and immunological barrier preventing viral transmission from the maternal to fetal circulation. [123] [124] [125] The preponderance of evidence to date suggests that adverse neurodevelopmental effects of SARS-CoV-2 infection, at least with the ancestral strain and strains preceding the B.1.617.2 (Delta) variant, are more likely to occur via maternal and placental immune activation and downstream impact on the developing fetal brain, rather than via direct fetal infection with SARS-CoV-2 in utero. [30, 126] Population-level data suggests that rates of SARS-CoV-2 positivity among newborns in SARS-CoV-2 exposed pregnancies range from 1-3% [87, [127] [128] [129] [130] [131] , with placental infection being a relatively rare event. One metaanalysis of case reports and case series estimated the rate of placental infection as 7%, [132] although prospective studies have identified even lower rates of placental limited to case reports. [136] Consistent with the observed low rate of placental infection and vertical transmission, data are now available from completed pregnancies exposed to SARS-CoV-2 during all developmental windows (first through third trimesters). To date, no characteristic congenital syndrome has emerged after prenatal SARS-CoV-2 exposure that would suggest direct fetal infection. [129, 130, 137, 138] Prenatal neuroimaging studies in pregnant cohorts have similarly failed to identify evidence of grossly-visible fetal intracranial pathology associated with maternal SARS-CoV-2 infection, though the small number of women included with severe or critical illness versus mild disease may limit generalizability of these findings. [139, 140] All these data point to maternal and placental immune activation and consequent fetal neuroimmune activation as primary drivers of neurodevelopmental morbidity in SARS-CoV-2-exposed offspring, rather than direct placental and fetal brain infection as has been observed with Zika virus or maternal CMV infection. [1, 2] 

Despite the aforementioned observational data against direct fetal infection as a major mechanism of risk to the developing fetal brain, animal and cellular models have demonstrated the potential for SARS-CoV-2 to directly infect fetal brain tissue, should the placental barrier be broached. A comprehensive analysis of fetal brain sequencing data from publicly available datasets identified low expression of canonical Spike (S) protein interactors ACE2 and TMPRSS2, but high expression of novel S protein interactors throughout gestation, with highest expression occurring in the second and third trimesters, suggestive of increased vulnerability during this window of gestation. [141] Limited evidence from adult human and animal models suggest that the SARS-CoV-2 virus can bypass or disrupt the blood brain barrier and gain access to neurological tissue. [142] [143] [144] Models using cerebral organoids with proteomic signatures similar to fetal brain tissue [145] have provided evidence of SARS-CoV-2 capability of neuroinvasion and neurotropism for the choroid plexus, cortical neurons, and glial cells. [144, [146] [147] [148] Taken together, these data raise the possibility that neurodevelopment at the J o u r n a l P r e -p r o o f cellular level could be directly impacted by prenatal infection with SARS-CoV-2, if viral particles gain access to the fetal circulation.

A key caveat in interpreting the available data is that observations primarily reflect the effects of ancestral viral strains, while less is known about placental and fetal effects of recent variants of concern, in particular the Delta and Omicron variants. It is plausible that mutations associated with enhanced immune escape or transmissibility could impact the risk for transplacental infection. Unfortunately, detecting anything other than a large or abrupt increase in vertical transmission will require the accumulation of data over time.

Recent evidence showing a near 2-fold increased risk of stillbirth associated with maternal SARS-CoV-2 infection, with a greater magnitude of association during the Deltapredominant period of the COVID-19 pandemic, [149] has raised concerns that the SARS-CoV-2 virus itself might be directly responsible for adverse pregnancy outcomes. [136] Of critical importance is whether Delta-variant SARS-CoV-2 infection may differentially affect either a) placental function or b) the integrity of the placental barrier to infection and thus the susceptibility for vertical transmission and/or more direct effects on the developing fetal brain.

As previously noted, the emergence of new strains complicates generalizations about SARS-CoV-2 mechanisms of risk. Delta variant infections have been linked to higher viral loads [150] and an increased risk of hospitalizations [151] in non-pregnant individuals compared to prior variants, as well as increased severity of maternal disease in pregnancy. [152] [153] [154] Delta spike P681R mutation may also affect virulence and tissue tropism by enhanced S protein cleavability by furin, [155, 156] a transmembrane serine protease that is widely expressed by both the placental syncytiotrophoblast [157, 158] and fetal brain tissue. [141] Although a characteristic histopathological signature associated with maternal SARS-CoV-2 infection was not clearly identified with the ancestral strain,[87,88,159,160] "SARS-CoV-2 placentitis"the triad of histocytic intervillositis, perivillous fibrin, and villous trophoblastic necrosis in the setting of SARS-CoV-2 infection-has emerged as a histopathologic entity observed in association with both Alpha-and Delta-variant maternal SARS-CoV-2 infections, and has been linked to poor J o u r n a l P r e -p r o o f pregnancy outcomes including stillbirth in case reports. [161, 162] Although definitive evidence linking Delta-variant SARS-CoV-2 placentitis to increased risk for fetal infection is lacking to date, these observations suggest the biological possibility that prenatal Delta-variant SARS-CoV-2 could lead to global placental dysfunction, and breach of the placental immune barrier.

Prenatal SARS-CoV-2 exposure may also impact offspring neurodevelopment by contributing directly to adverse pregnancy outcomes. Indeed, SARS-CoV-2 infection acquired during pregnancy is associated with an increased risk of preeclampsia and preterm birth, [27, 129, [163] [164] [165] [166] outcomes which have independently been associated with offspring neurodevelopmental risk. [167, 168] The association between SARS-CoV-2 and preterm birth complicates studies of neurodevelopment, because it impacts the ability to understand specificity of virus-associated risk. If the mechanism of action of SARS-CoV-2 is simply to cause maternal illness that, in more severe cases, contributes to preterm delivery, then full-term offspring should not experience elevated rates of neurodevelopmental sequelae, and efforts to investigate specific viral effects are unlikely to be necessary. On the other hand, if this is not the case, it is critically important to understand the additive, or multiplicative, effect of the virus itself when preterm delivery occurs in the setting of or following maternal SARS-CoV-2 infection.

To date, only one study has addressed this question[27] and found that maternal infection was still associated with greater risk for 12-month neurodevelopmental adverse outcomes after adjustment for preterm delivery. When analysis was limited to full-term deliveries, the magnitude of risk was diminished, and the 95% confidence interval included no effect, but risk in numeric terms remained substantial. While preliminary, this highlights the importance of wellcontrolled follow-up studies that evaluate the impact of gestational age at delivery.

To date, efforts to understand maternal immune activation have largely focused on either large-scale human epidemiologic studies or human biological materials, which may indicate risk but are vulnerable to confounding, and animal models of disease, which allow more complete experimental control but may not recapitulate key elements of brain development. Cellular models can bridge these two investigative forms, particularly models that make use of primary J o u r n a l P r e -p r o o f human cells that may retain epigenomic effects of environment and infection. For example, in prior work, patient-derived microglia-like cells differentiated from peripheral blood monocyte precursors demonstrated abnormal phagocytosis of synaptic materials, providing a potential mechanism of disease for schizophrenia or related disorders. [169] More recently, these protocols have been adapted to generate microglia-like cells from umbilical cord blood, [170] providing a more direct means of characterizing the impact of in utero exposures for a specific individual.

Another emerging strategy utilizes Hofbauer cells, fetal placental macrophages which may be isolated from the placenta after delivery and cultured. [123] An advantage of these cells is that, like microglia, they are yolk-sac-derived, and thus may closely mimic the exposures and developmental processes of brain microglia. [171] Multiple published protocols also enable the generation of microglia-like cells from induced pluripotent stem cells (iPS). A limitation of this approach, compared to the prior two, is that generation of iPS cells entails disruption of the epigenome, prohibiting epigenomic investigations. [172] Alternatively, an advantage is that iPS can be expanded, banked, and used for large-scale experiments or screens. Regardless of source, such models provide an opportunity to conduct mechanistic studies in human cells to understand SARS-CoV-2-mediated effects.

The data presented here demonstrate the potential for maternal SARS-CoV-2 infection to drive maternal, placental and fetal immune activation, and thus the potential for adverse fetal neurodevelopmental programming. Future studies will need to evaluate whether the fetoplacental immune responses observed in maternal SARS-CoV-2 infection are associated with longer-term neurodevelopmental and neuropsychiatric morbidity in offspring. While the majority of available data are for third trimester infections or active infection at the time of delivery, the implications of infection earlier in gestation on offspring outcomes will be critical to a holistic understanding of risk. An important observation is that immune activation need not impact only fully-differentiated cellsindeed, by impacting yolk sac-derived precursor cells, an early (e.g., 

• SARS-CoV-2 infection in pregnancy is known to confer a risk of increased morbidity and mortality for the mother, but data are lacking regarding the impact of maternal SARS-CoV-2 infection on the developing fetal brain. • Placental and fetal infection with SARS-CoV-2 have been rare to date; SARS-CoV-2 infection in pregnancy appears most likely to impact fetal brain development via maternal and placental immune activation. • Maternal, placental, and fetal immune activation have been observed in SARS-CoV-2 infection during pregnancy, and adverse neurodevelopmental outcomes have been reported in early follow-up studies of offspring. • Maternal and placental immune activation may impact the placenta and developing fetal brain via induction of immune activation and pro-inflammatory cytokine production, dysregulation of serotonin/other neurotransmitter signaling, and increased oxidative stress.

• What will neurodevelopmental outcomes be in children exposed to prenatal SARS-CoV-2 infection at age 2 and beyond? • Does trimester of maternal infection impact offspring neurodevelopmental outcomes? • Does prenatal SARS-CoV-2 infection that results in placental infection and/or vertical transmission have a differential (e.g. more severe) impact on offspring neurodevelopmental outcomes? Large, population-level studies will be needed to answer this question given the relative rarity of placental infection and vertical transmission. • How do variant strain and severity of maternal illness impact offspring neurodevelopmental risk?

• What is the impact of fetal sex on offspring neurodevelopmental risk? • How do other pre-and perinatal exposures, and the postnatal environment, interact with prenatal SARS-CoV-2 infection to impact offspring neurodevelopmental risk? • How can cellular models be leveraged to understand neurodevelopmental risk at the individual level and guide precision interventions and/or therapeutics?

• Although placental infection and vertical transmission after maternal SARS-CoV-2 infection are rare entities to date, early studies suggest that prenatal exposure to SARS-CoV-2 infection is associated with adverse neurodevelopmental outcomes in children at 3 months to 1.5 years of age.

• Evaluating neurodevelopmental outcomes in children exposed to maternal SARS-CoV-2 infection prenatally at 2 years of age and beyond will be critical to gaining a full understanding of offspring neurodevelopmental risk. • The impact of additive or synergistic maternal risk factors such as maternal obesity, diabetes or hypertension, maternal substance use disorder, or other maternal bacterial or viral infections in pregnancy on offspring neurodevelopmental outcomes will be an important area for future study.

• The impacts of virus and host factors such as variant strain, maternal disease severity, and fetal sex on offspring neurodevelopmental risk will be important to parse in future studies.

Zika Virus Associated with Microcephaly

Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention

Long-term Risk of Neuropsychiatric Disease After Exposure to Infection In Utero

Infections and Brain Development

Contributions of maternal and fetal antiviral immunity in congenital disease

Maternal Infection During Pregnancy and Autism Spectrum Disorders

Influence of infection during pregnancy on fetal development

The fetal origins of mental illness

Spanish Influenza Pandemic: Mechanisms of Psychosis Risk. Front

Maternal infection during pregnancy and risk of autism spectrum disorders: A systematic review and meta-analysis

Maternal hospitalization with infection during pregnancy and risk of autism spectrum disorders

Adult Schizophrenia Following Prenatal Exposure to an Influenza Epidemic

Maternal Immune Activation and Neuropsychiatric Illness: A Translational Research Perspective

Immune involvement in schizophrenia and autism: etiology, pathology and animal models

The Healthy Brain and Child Development Study-Shedding Light on Opioid Exposure, COVID-19, and Health Disparities

COVID-19 Infection During Pregnancy and Risk of Neurodevelopmental Disorders in Offspring: Time for Collaborative Research

SARS-CoV-2-associated cytokine storm during pregnancy as a possible risk factor for neuropsychiatric disorder development in post-pandemic infants

Inflammatory cytokines induced by severe acute respiratory syndrome coronavirus 2 infection during pregnancy may alter fetal brain development predisposing the offspring to neurodevelopmental disorders

Data on COVID-19 during Pregnancy: Severity of Maternal Illness

Universal Screening for SARS-CoV-2 in Women Admitted for Delivery

Countering COVID-19 vaccine hesitancy in pregnancy: the "4 Cs

Neurodevelopmental outcomes at one year in offspring of mothers who test positive for SARS-CoV-2 during pregnancy

Risks associated with viral infections during pregnancy

Viral infections during pregnancy

SARS-CoV-2 Infection in Pregnant Women: Neuroimmune-Endocrine Changes at the Maternal-Fetal Interface

Risks associated with viral infections during pregnancy

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions

Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives

Persistence of neuropsychiatric symptoms associated with SARS-CoV-2 positivity among a cohort of children and adolescents

Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study

Coronavirus Infections in the Nervous System of Children: A Scoping Review Making the Case for Long-Term Neurodevelopmental Surveillance

Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study

Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19

Association Between the COVID-19 Pandemic and Infant Neurodevelopment: A Comparison Before and During COVID-19. Front Pediatr 9

Impact of the COVID-19 Pandemic on Early Child Cognitive Development: Initial Findings in a Longitudinal Observational Study of Child Health

Birth during the COVID-19 pandemic, but not maternal SARS-CoV-2 infection during pregnancy, is associated with lower neurodevelopmental scores at 6-months

Neurodevelopmental outcomes of infants secondary to in utero exposure to maternal SARS-CoV-2 infection: A national prospective study in Kuwait

Maternal Immune Activation and Autism Spectrum Disorder: From Rodents to Nonhuman and Human Primates

Advancing Autism Research From Mice to Marmosets: Behavioral Development of Offspring Following Prenatal Maternal Immune Activation

Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring

Modeling an autism risk factor in mice leads to permanent immune dysregulation

Maternal immune activation alters nonspatial information processing in the hippocampus of the adult offspring

Manganese-enhanced magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of schizophrenia

Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism

Brain changes in a maternal immune activation model of neurodevelopmental brain disorders

Maternal Immune Activation and Autism Spectrum Disorder: From Rodents to Nonhuman and Human Primates

Maternal Immune Activation by Poly I:C as a preclinical Model for Neurodevelopmental Disorders: A focus on Autism and Schizophrenia

Beyond infection -Maternal immune activation by environmental factors, microglial development, and relevance for autism spectrum disorders

Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems

Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring

The risk for behavioural deficits is determined by the maternal immune response to prenatal immune challenge in a neurodevelopmental model

The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring

Maternal IL-17A in autism

Maternal immune activation alters fetal brain development through interleukin-6

A novel model for prenatal brain damage. II. Long-term deficits in hippocampal cell number and hippocampal-dependent behavior following neonatal GABAA receptor activation

Effects of prenatal infection on brain development and behavior: a review of findings from animal models

IL-1 receptor antagonist protects against placental and neurodevelopmental defects induced by maternal inflammation

Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling

Maternal IL-6 during pregnancy can be estimated from newborn brain connectivity and predicts future working memory in offspring

Maternal Immune Activation During the Third Trimester Is Associated with Neonatal Functional Connectivity of the Salience Network and Fetal to Toddler Behavior

Maternal Systemic Interleukin-6 During Pregnancy Is Associated With Newborn Amygdala Phenotypes and Subsequent Behavior at 2 Years of Age

Maternal Interleukin-6 concentration during pregnancy is associated with variation in frontolimbic white matter and cognitive development in early life

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

COVID-19: immunopathology and its implications for therapy

Maternal immune responses and obstetrical outcomes of pregnant women with COVID-19 and possible health risks of offspring

Cytokine release syndrome in severe COVID-19

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19: a case for inhibiting IL-17?

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

The impact of COVID-19 infection on the cytokine profile of pregnant women: A prospective case-control study

Pregnancy alters interleukin-1 beta expression and antiviral antibody responses during severe acute respiratory syndrome coronavirus 2 infection

Maternal respiratory SARS-CoV-2 infection in pregnancy is associated with a robust inflammatory response at the maternal-fetal interface

Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses

SARS-CoV-2 Infects Syncytiotrophoblast and Activates Inflammatory Responses in the Placenta

Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic

SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers

Maternal-Fetal Immune Responses in Pregnant Women Infected with SARS-CoV-2. Res Sq

The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate

Single-cell immunophenotyping of the fetal immune response to maternal SARS-CoV-2 infection in late gestation

Single-cell immunophenotyping of the fetal immune response to maternal SARS-CoV-2 infection in late gestation

Maternal Immune Activation Alters Fetal Brain Development and Enhances Proliferation of Neural Precursor Cells in Rats

Distinct trans-placental effects of maternal immune activation by TLR3 and TLR7 agonists: implications for schizophrenia risk

Influence of poly(I:C) variability on thermoregulation, immune responses and pregnancy outcomes in mouse models of maternal immune activation

Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response

A transient placental source of serotonin for the fetal forebrain

Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain

Serotonin modulates the response of embryonic thalamocortical axons to netrin-1

The Influence of Maternal Metabolic State and Nutrition on Offspring Neurobehavioral Development: A Focus on Preclinical Models

Placental serotonin signaling, pregnancy outcomes, and regulation of fetal brain developmentdagger

Placental serotonin: implications for the developmental effects of SSRIs and maternal depression

The impact of leptin on perinatal development and psychopathology

Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice

Preliminary evidence for a modulation of fetal dopaminergic development by maternal immune activation during pregnancy

Maternal Immune Activation Disrupts Dopamine System in the Offspring

Changes in melanocortin expression and inflammatory pathways in fetal offspring of nonhuman primates fed a high-fat diet

Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia

Brain changes in a maternal immune activation model of neurodevelopmental brain disorders

Maternal immune activation induced by lipopolysaccharide triggers immune response in pregnant mother and fetus, and induces behavioral impairment in adult rats

Maternal immune activation in mice disrupts proteostasis in the fetal brain

The microbiota regulate neuronal function and fear extinction learning

Apoptosis and microglial activation in influenza encephalopathy

Controversies and prospects about microglia in maternal immune activation models for neurodevelopmental disorders

Prenatal infection leads to ASD-like behavior and altered synaptic pruning in the mouse offspring

Maternal immune activation-induced PPARgamma-dependent dysfunction of microglia associated with neurogenic impairment and aberrant postnatal behaviors in offspring

Microglia and Beyond: Innate Immune Cells As Regulators of Brain Development and Behavioral Function

Synaptic pruning by microglia is necessary for normal brain development

Function and Dysfunction of Microglia during Brain Development: Consequences for Synapses and Neural Circuits

The Complement System: An Unexpected Role in Synaptic Pruning During Development and Disease

Maternal Immune Activation During the Third Trimester Is Associated with Neonatal Functional Connectivity of the Salience Network and Fetal to Toddler Behavior

Maternal immune activation during pregnancy impacts on brain structure and function in the adult offspring

Gatekeepers of the fetus: Characterization of placental macrophages

Placental Immune Responses to Viruses: Molecular and Histo-Pathologic Perspectives

Influenza, immune system, and pregnancy

Classification system and case definition for SARS-CoV-2 infection in pregnant women, fetuses, and neonates

Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Outcomes of Neonates Born to Mothers With Severe Acute Respiratory Syndrome Coronavirus 2 Infection at a Large Medical Center

Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy -SET-NET, 16 Jurisdictions

Infant Outcomes Following Maternal Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): First Report From the Pregnancy Coronavirus Outcomes Registry (PRIORITY) Study

Vertical transmission of SARS-CoV-2: consider the denominator

Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis

Inefficient Placental Virus Replication and Absence of Neonatal Cell-Specific Immunity Upon Sars-CoV-2 Infection During Pregnancy

Evidence and possible mechanisms of rare maternal-fetal transmission of SARS-CoV-2

Unlikely SARS-CoV-2 Transmission During Vaginal Delivery

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infecting Pregnant Women and the Fetus, Intrauterine Transmission, and Placental Pathology During the Coronavirus Disease 2019 (COVID-19) Pandemic: It's Complicated

COVID-19 in pregnancy: the foetal perspective-a systematic review

POTENTIAL RISK OF BRAIN DAMAGE AND POOR DEVELOPMENTAL OUTCOMES IN CHILDREN PRENATALLY EXPOSED TO SARS-COV-2: A SYSTEMATIC REVIEW

SARS-CoV-2 infection during pregnancy: Does fetal MRI show signs of impaired fetal brain development?

Ultrasound and Doppler findings in pregnant women with SARS-CoV-2 infection

Novel Targets of SARS-CoV-2 Spike Protein in Human Fetal Brain Development Suggest Early Pregnancy Vulnerability

Infection Mechanism of SARS-COV-2 and Its Implication on the Nervous System

SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration

Neuroinvasion of SARS-CoV-2 in human and mouse brain

Human Cerebral Organoids and Fetal Brain Tissue Share Proteomic Similarities

Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium

SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids

SARS-CoV-2 targets glial cells in human cortical organoids

Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization -United States

2021) Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge

Association of the Delta (B.1.617.2) Variant of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) With Pregnancy Outcomes

Impact of SARS-CoV-2 variant on the severity of maternal infection and perinatal outcomes: Data from the UK Obstetric Surveillance System national cohort

Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant

Proteolytic activation of SARS-CoV-2 spike protein

Single-Cell RNA-seq Identifies Cell Subsets in Human Placenta That Highly Expresses Factors Driving Pathogenesis of SARS-CoV-2

Term Human Placental Trophoblasts Express SARS-CoV-2 Entry Factors ACE2, TMPRSS2, and Furin

Placental Pathology in COVID-19

Placenta histopathology in SARS-CoV-2 infection: analysis of a consecutive series and comparison with control cohorts

Covid Placentitis: Statement from the RCPI Faculty of Pathology and the Institute of Obstetricians and Gynaecologists

SARS-CoV-2 placentitis associated with B.1.617.2 (Delta) variant and fetal distress or demise. The Journal of Infectious Diseases In press

Association of SARS-CoV-2 Test Status and Pregnancy Outcomes

Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study

Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19)

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

Association of Preeclampsia in Term Births With Neurodevelopmental Disorders in Offspring

Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks' gestation in France in 2011: EPIPAGE-2 cohort study

Increased synapse elimination by microglia in schizophrenia patientderived models of synaptic pruning

Umbilical cord blood-derived microglia-like cells to model COVID-19 exposure

Single cell profiling of Hofbauer cells and fetal brain microglia reveals shared programs and functions

2022) Patient-derived in vitro models of microglial function and synaptic engulfment in schizophrenia

Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages

Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors

Development and homeostasis of "resident" myeloid cells: the case of the microglia